ESC 2024: elevated blood pressure and hypertension
International ESC Current
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy JW, et al. Eur Heart J. 2024;45:3912–4018
DOI 10.1093/eurheartj/ehae178 · Summary checked against the source: 2026-11
At a glance
- New three-way split: non-elevated BP (<120/70), elevated BP (120–139/70–89) and hypertension (≥140/90). [p. 3937]
- Treat by risk in the elevated band. Increased risk means established CVD, moderate–severe CKD, hypertension-mediated organ damage (HMOD), diabetes, familial hypercholesterolaemia, SCORE2/SCORE2-OP ≥10%, or 5–<10% plus risk modifiers. [p. 3963, 3990]
- Hypertension (≥140/90): start drugs promptly, whatever the risk. [p. 3991]
- Target systolic 120–129 (diastolic 70–79) for most adults, if tolerated. When that isn't possible, use "as low as reasonably achievable" (ALARA). [p. 3966]
- Start with a low-dose two-drug single pill: ACEi/ARB + CCB or diuretic. Step up to three drugs, then add spironolactone. [p. 3960]
- Keep treating lifelong, even after 85, if tolerated. [p. 3991]
- Renal denervation is not first-line. It's an option (IIb) only for resistant hypertension at an experienced centre. [p. 3981, 3991]
Classification and out-of-office thresholds
Adapted from ESC 2024 Table 5 and Figure 6 [p. 3933, 3937]
| Office | Home | Daytime ABPM | 24-h ABPM | Night ABPM | |
|---|---|---|---|---|---|
| Non-elevated | <120/70 | <120/70 | <120/70 | <115/65 | <110/60 |
| Elevated | 120/70 to <140/90 | 120/70 to <135/85 | 120/70 to <135/85 | 115/65 to <130/80 | 110/60 to <120/70 |
| Hypertension | ≥140/90 | ≥135/85 | ≥135/85 | ≥130/80 | ≥120/70 |
Diagnosing hypertension [p. 3990]
flowchart TD
A["Screening for hypertension by office BP"] --> NE["Non-elevated<br/><120/70"]
A --> EL["Elevated<br/>120–139 / 70–89"]
A --> H1["Hypertension<br/>140–159 / 90–99"]
A --> H2["Hypertension<br/>160–179 / 100–109"]
A --> H3["Hypertension<br/>≥180/110"]
NE --> AGE{"Age ≥40?"}
AGE -- No --> S3["Opportunistic screening<br/>at least every 3 years (IIa)"]
AGE -- Yes --> S1["Opportunistic screening<br/>at least every year (IIa)"]
EL --> RISK{"High CVD-risk condition, or<br/>SCORE2/SCORE2-OP ≥10%, or<br/>SCORE2 5–<10% + risk modifiers?"}
RISK -- No --> S1
RISK -- Yes --> C1["Confirm BP, preferably with<br/>home or ambulatory BP (I)"]
H1 --> C1
H2 --> C2["Confirm BP promptly, preferably with<br/>home or ambulatory BP (I)"]
H3 --> EM["Evaluate for hypertensive emergency (I)"]
Adapted from ESC 2024 Figure 10 [p. 3944]
If home or ambulatory BP isn't feasible, confirm with repeated office readings on more than one visit. Confirm BP of 160–179/100–109 within about a month. [p. 3990]
Class I: measurement and work-up
- Use a validated, calibrated device and a standard technique. Measure opportunistically in every adult and tell them the result.
- Measure BP in both arms at the first visit. If they differ by >10 mmHg systolic, use the higher arm from then on.
- Feel the pulse to check for atrial fibrillation.
- Every patient with hypertension needs serum creatinine, eGFR, urine ACR and a 12-lead ECG. Repeat creatinine, eGFR and ACR at least yearly if CKD is moderate to severe.
- Echocardiography if the ECG is abnormal or there are cardiac symptoms. Fundoscopy if BP >180/110, or the patient has diabetes.
- Screen anyone diagnosed before age 40 for secondary hypertension. In obese young adults, start with sleep apnoea.
Class III
- Routine genetic testing in hypertension.
Lifestyle [p. 3990–3991]
Class I
- Sodium about 2 g/day (about 5 g of salt, or a teaspoon).
- 150 min/week of moderate aerobic exercise (or 75 min vigorous), plus resistance training 2–3 times a week.
- BMI 20–25. Waist <94 cm in men, <80 cm in women.
- Mediterranean or DASH diet.
- Alcohol below about 100 g/week; avoiding alcohol is best.
- Free sugars below 10% of energy. Discourage sugar-sweetened drinks from childhood.
- Stop smoking.
When to start drugs
Adapted from ESC 2024 Table 14 [p. 3963]
| Non-elevated (<120/70) | Elevated (120/70 to 139/89): lower risk | Elevated: sufficiently high risk | Hypertension (≥140/90) | |
|---|---|---|---|---|
| Who | SBP 120–129 (any risk), or SBP 130–139 with 10-year CVD risk <10% and no high-risk condition or risk modifier | SBP 130–139 and one of: a high-risk condition (established CVD, diabetes, CKD, FH or HMOD), 10-year risk ≥10%, or risk 5–<10% plus risk modifiers or abnormal risk-tool tests | Everyone: all are treated as high enough risk to benefit from drugs | |
| Treatment | Lifestyle for prevention; screen BP and CVD risk opportunistically | Lifestyle measures; monitor BP and CVD risk yearly | Lifestyle, then drugs after a 3-month delay if confirmed BP is still ≥130/80 | Lifestyle and drugs straight away |
| Target | Keep BP <120/70 | Aim for 120–129 / 70–79 | Aim for 120–129 / 70–79 | Aim for 120–129 / 70–79 |
Class IIa: deferring drugs until BP ≥140/90
Start drugs only from ≥140/90 when there's pre-treatment symptomatic orthostatic hypotension, age ≥85, clinically significant moderate-to-severe frailty, or limited life expectancy (<3 years). [IIa, B · p. 3963]
Drug treatment
flowchart TD
S["Low-dose double combination*<br/>ACEi or ARB / CCB / diuretic (I)"] --> C1{"Controlled after 1–3 months?<br/>(1-month review preferred)"}
C1 -- Yes --> F["Follow up at least yearly"]
C1 -- No --> T["Low-dose triple combination<br/>ACEi or ARB / CCB / diuretic (I)"]
T --> C2{"Controlled after 1–3 months?"}
C2 -- Yes --> F
C2 -- No --> M["Maximally tolerated triple combination<br/>ACEi or ARB / CCB / diuretic (I)"]
M --> C3{"Controlled after 1–3 months?"}
C3 -- Yes --> F
C3 -- No --> R["Apparent resistant hypertension<br/>refer to hypertension clinic (IIa)<br/>test for adherence (IIa)<br/>add spironolactone (IIa)"]
X["*Initial monotherapy preferred: elevated BP band,<br/>moderate–severe frailty, symptomatic<br/>orthostatic hypotension, age ≥85"] -.-> S
B["At any step: add a beta-blocker for a compelling<br/>indication: angina, post-MI, systolic HF,<br/>heart-rate control (I)"] -.-> T
Adapted from ESC 2024 Figure 18 [p. 3960]
Class I
- First-line: ACE inhibitors, ARBs, dihydropyridine CCBs and diuretics (thiazides and thiazide-like: chlorthalidone, indapamide).
- Beta-blockers go with another class only when there's a compelling indication.
- Initial combination for most with confirmed BP ≥140/90. Preferred pair: RAS blocker + DHP CCB or diuretic, in a single pill.
- If two drugs fail, move to three: RAS blocker + DHP CCB + thiazide or thiazide-like, preferably one pill.
- Take the pills at whatever time of day suits the patient best.
Targets [p. 3966]
- Systolic 120–129 for most adults, if tolerated.
- If that isn't tolerated: systolic as low as reasonably achievable (ALARA).
Class IIa
Class IIb
Special groups [p. 3991–3992]
Class I
- Elevated BP with diabetes: after up to 3 months of lifestyle change, start drugs if BP is still ≥130/80.
- Target systolic 120–129 if tolerated.
- Prediabetes or obesity: drugs at ≥140/90, or at 130–139/80–89 if 10-year risk is ≥10% or a high-risk condition is present, after 3 months of lifestyle change.
Class I
- Moderate–severe CKD with BP ≥130/80: lifestyle plus drugs.
- eGFR >30: target systolic 120–129 if tolerated. Individualise targets for lower eGFR or a kidney transplant.
- SGLT2 inhibitor if eGFR >20.
Class I
- Post-MI: beta-blocker + RAS blocker.
- Angina: beta-blocker and/or CCB.
- HFrEF/HFmrEF: ACEi (ARB if intolerant) or ARNI, beta-blocker, MRA, SGLT2 inhibitor.
- HFpEF: SGLT2 inhibitor.
Class I
- Gestational or chronic hypertension: start drugs at confirmed office ≥140/90.
- Target <140/90, but diastolic not below 80.
- First-line: DHP CCB (preferably extended-release nifedipine), labetalol, methyldopa.
- Low- to moderate-intensity exercise for all pregnant women who can.
Class III
- RAS blockers in pregnancy.
Class I
- Under 85 and not moderately or severely frail: treat as for younger adults.
- Check for orthostatic hypotension before starting or stepping up drugs (sit or lie 5 min, then measure at 1 and/or 3 min standing).
- Orthostatic hypotension with supine hypertension: switch the offending drug rather than just reducing treatment.
Resistant hypertension [p. 3981–3982]
- Add spironolactone when BP stays uncontrolled on first-line drugs.
- Spironolactone ineffective or not tolerated: switch to eplerenone, or add a beta-blocker. Next options: centrally acting drug, alpha-blocker, hydralazine or potassium-sparing diuretic.
- Catheter-based renal denervation for uncontrolled resistant hypertension on three drugs. Only at a medium- to high-volume centre, after a multidisciplinary assessment and if the patient wants it.
Class III
- Renal denervation as first-line treatment.
- Renal denervation when eGFR <40 or there's a secondary cause.
- Renal artery angioplasty without a haemodynamically significant stenosis.
Clinical pearls
- ESC still defines hypertension at ≥140/90. The 120–139/70–89 band is called "elevated BP".
- The on-treatment target is a range (120–129), not just a ceiling.
- The SCORE2 high-risk cut-off is 10% (AHA's PREVENT cut-off is 7.5%).
- In ICH, ESC aims for 140–160 (AHA aims for 130–<140).
- Spironolactone for resistant hypertension is IIa in ESC but Class 1 in AHA.
Classes and levels of evidence
How ESC 2024 grades its recommendations. Adapted from ESC 2024 Tables 1 and 2 [p. 3918–3919]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| Class I | Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective | is recommended or is indicated |
| Class IIa | Weight of evidence or opinion is in favour of usefulness or efficacy | should be considered |
| Class IIb | Usefulness or efficacy is less well established by evidence or opinion | may be considered |
| Class III | Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful | is not recommended |
| Level | Meaning |
|---|---|
| Level A | Data from multiple randomised clinical trials or meta-analyses |
| Level B | Data from a single randomised clinical trial or large non-randomised studies |
| Level C | Consensus of expert opinion and/or small studies, retrospective studies, registries |
Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.